AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
WRBY

Warby Parker Inc. Class A Common Stock (WRBY) fair value

Healthcare · Medical Instruments & Supplies · NYSE · United States
$25.91+0.93%
Market cap $3.2BNext earnings 2026-11-05Updated Oct 20, 2026
Add earnings to calendarGoogle
Our verdict
Trades 156% above our fair value
Price
$25.91
Model fair valueConfidence: medium
$10.10
Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionWarby Parker Inc. Class A Common Stock (WRBY)
Fair value (3 models)
Not available
ACCE price target
$24.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $25.91 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
45
out of 100
Analysts
71% buy
14 covering
P/E
431.8x
forward 42.1x
1-year return
+16.9%
Dividend yield
0.00%

Warby Parker Inc. Class A Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Warby Parker sells eyeglasses, sunglasses and contact lenses under its own brand, mostly direct to consumers through roughly 300 owned stores and its website, with a growing optometry and eye-exam business attached. The structural case rests on a 53.1% gross margin, which is high for a retailer and reflects owning the design, sourcing and distribution chain rather than buying branded frames at wholesale. Revenue is growing 9.8%, but the operating margin is still -3.6%, so the company has not yet shown it can convert that gross profit into earnings at scale. At a forward P/E of 54.3 against a trailing 409.8, the market is pricing in a sharp earnings ramp that the current numbers do not yet show, and with ROE at 2.1% and no index membership, the name needs to clear a high bar before it earns a position. A deeper look is worth it only if the store-level economics and the path to operating breakeven hold up in the filings.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
  • high
    Earnings declining despite revenue growth
    Revenue grew 9.8% year over year, but earnings fell 9.6%. Operating margin is -3.6% and net margin only +0.9%, so growth is not reaching the bottom line.
  • high
    Heavy short interest
    Short interest stands at 20.9% of ownership. Insiders recorded $6.44M in sales and no buys across the last 10 disclosed transactions.
  • moderate
    Valuation stretched on earnings
    Trailing P/E is 427.0 and EV/EBITDA is 51.7. The price sits 8.0% above the $24.00 ACCE price target, which also marks the stock as expensive against our own target.
  • moderate
    ACCE score drifting lower
    The composite score fell from 41 to 38 over 90 days. Valuation sub-score is weakest at 21, while quality is 42 and momentum 47.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 9.8% over the past year, and the five-year average growth rate is 17.2% per year.
  • Analysts rate the stock Buy or Strong Buy 71% of the time, and their mean price target sits 18.9% above the share price.
  • Free cash flow over the last 12 months reached $44M, showing the business generates real cash.
Why it could disappoint
  • Net margin is only 0.9% and return on invested capital is 0.2%, so little profit comes from the money the business uses.
  • The trailing P/E is 427.0x, against a forward P/E of 41.7x compared with a sector median of 24.1x.
  • The diluted share count rose 3.9% last fiscal year, so each share now represents a smaller slice of the company.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where WRBY's valuation models land
Price
$25.91
Model fair valueConfidence: medium
$10.10
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish71% buy · 14 covering analysts
● Strong buy 8● Buy 2● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+11.0%
1 month
+11.0%
3 months
+5.5%
6 months
+13.6%
YTD
+18.9%
1 year
+16.9%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
11 Oct 2026, 00:00 CESTACCE price target$24.00first publication$25.30
4 Oct 2026, 00:00 CESTFair value$6.51$6.92$27.03
1 Oct 2026, 00:00 CESTFair value$6.92$6.59$27.47
29 Sept 2026, 00:00 CESTFair value$6.59$7.10$26.71
26 Sept 2026, 00:00 CESTFair value$7.10$6.86$26.27
23 Sept 2026, 00:00 CESTFair value$6.86$6.75$23.25
21 Sept 2026, 00:00 CESTFair value$6.75$5.95$22.50
18 Sept 2026, 00:00 CESTFair value$5.95$6.79$23.55
15 Sept 2026, 00:00 CESTFair value$6.79$6.92$24.71
13 Sept 2026, 00:00 CESTFair value$6.92$7.02$24.71

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full WRBY page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth40Value21Quality42Momentum77Total45
Valuation
Trailing P/E
431.8x
Forward P/E
42.1x
PEG
no data
P/B
7.36x
EV / Revenue
3.1x
Book value/sh
$3.18
Enterprise value
$2.8B
Profitability
ROE
2.1%
FCF yield
1.37%
ROIC
0.2%
Health and risk
Debt / equity
0.63
Dividend yield
0.00%
Beta
1.90

Price

+21.9% · 1Y

Ask anything about WRBY

Answered from Warby Parker Inc. Class A Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 0.0x431.8xhigh 431.8x
ROEbetter than 33% of peers
low -9%2%high 25%
Div yieldbetter than 50% of peers
low 0.0%0.0%high 1.5%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
WRBY Warby Parker Inc. Class A Common Stock$25.91--431.8x2.1%4245
ICUI ICU Medical Inc. Common Stock$166.62$11151% above134.7x1.4%4350
ALIF-B.ST AddLife AB (publ)kr 184.20kr 13339% above35.0x11.5%5454
ANN.AX Ansell LimitedA$46.27A$4016% above21.6x10.5%6775
BONEX.ST Bonesupport Holding AB (publ)kr 332.60--81.5x24.5%8872
MMED MiniMed Group Inc. Common Stock$18.34----8.7%4354
STVN Stevanato Group S.p.A. Ordinary Shares$19.49$1257% above34.2x9.1%6347

Sector report card

Where WRBY ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 15, 2026
    Warby Parker to Announce Third Quarter 2026 Financial Results on November 5, 2026
  • PR Newswire•Sep 15, 2026
    Gap Inc. Appoints Kirsten Green to Board of Directors
  • Business Wire•Sep 8, 2026
    Warby Parker Announces Participation in the Goldman Sachs 33rd Annual Global Retailing Conference
2 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 2
Form 4Insider transactionPeriod 2026-10-01
View on SEC →
Oct 2
Form 4Insider transactionPeriod 2026-10-01
View on SEC →
September 2026
Sep 4
Form 4Insider transactionPeriod 2026-09-02
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR